Evolution Wealth Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Evolution Wealth Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-467	Closed	-$51K	–	677
2021 Q3	$51K	Buy	467 +57	+14%	+$5.92K	0.01%	207
2021 Q2	$38K	Buy	410 +81	+25%	+$7.45K	0.01%	233
2021 Q1	$30K	Sell	329 -83	-20%	-$7K	0.01%	248
2020 Q4	$30K	Sell	412 -132	-24%	-$9.81K	0.01%	225
2020 Q3	$42K	Hold	544	–	–	0.01%	197
2020 Q2	$30K	Hold	544	–	–	0.01%	175
2020 Q1	$16K	Buy	544 +46	+9%	+$1.56K	0.01%	170
2019 Q4	$18K	Buy	+498	New	+$15.3K	﹤0.01%	237

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Evolution Wealth Advisors's HZNP Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2021, closing a stake of 467 shares — an estimated $51K sold.

Evolution Wealth Advisors first reported a position in HZNP in Q4 2019 and held it in 8 quarters. The position peaked at $51K in Q3 2021. 611 funds tracked by Wall St. Rank hold HZNP as of Q4 2021.

Evolution Wealth Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2021 after selling out during the quarter.
Evolution Wealth Advisors sold 467 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2021, an estimated $51K.
Evolution Wealth Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 8 quarters.
Evolution Wealth Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $51K in Q3 2021.
611 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.